This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Harwood Feffer LLP Announces Investigation Of Accretive Health, Inc.

NEW YORK, Feb. 27, 2013 /PRNewswire/ -- Harwood Feffer LLP ( is investigating potential claims against Accretive Health, Inc. ("Accretive Health" or the "Company") and its officers and directors on behalf of purchasers of Accretive Health common stock concerning false and misleading statements, omissions and fraudulent accounting practices.  More specifically, Harwood Feffer is investigating whether certain statements made by the Company between May 9, 2012 and February 26, 2013 regarding the Company's revenue and related projections were false and misleading because the Company engaged in improper revenue recognition practices during such time.

(Logo: )

Accretive Health is a provider of revenue cycle management services for hospitals and healthcare providers in the United States.  On February 26, 2013, Accretive Health announced that it would postpone the release of fourth quarter and full-year financial results because of concerns related to its revenue recognition practices under its revenue cycle management agreements with its customers.  Relatedly, the Company announced that it was withdrawing its financial guidance provided on November 12, 1012.  The market reacted swiftly to this news on February 27, 2013, causing the Company's stock price to drop nearly 30% in intra-day trading on heavy volume.

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts.  Please visit the Harwood Feffer LLP website ( for more information about the firm.

If you purchased Accretive Health common stock and suffered a loss and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs